ArticleJournal of immunology (Baltimore, Md. : 1950)2008
Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo.
Article in Journal of immunology (Baltimore, Md. : 1950), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 111 citations in OpenAlex.
- Trial
- Critical role of TLR activation in viral replication, persistence, and pathogenicity of Theiler's virus.Frontiers in immunology · 2023Review
- Regulating the regulatory T cells as cell therapies in autoimmunity and cancer.Frontiers in medicine · 2023Review
- Excessive Innate Immunity Steers Pathogenic Adaptive Immunity in the Development of Theiler's Virus-Induced Demyelinating Disease.International journal of molecular sciences · 2021Review
- Rapid Expansion of Virus-Specific CD4International journal of molecular sciences · 2020Article
- Sphingosine 1 phosphate receptor-1 (S1P1) promotes tumor-associated regulatory T cell expansion: leading to poor survival in bladder cancer.Cell death & disease · 2019Article
- Regulatory T cells in autoimmune disease.Nature immunology · 2018Review
- Serum Cytokine Profile in Patients with Chronic Rhinosinusitis with Nasal Polyposis Infected by Aspergillus flavus.Annals of laboratory medicine · 2018Article
- Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials.Cytotherapy · 2017Article
- [Regulatory T-cells in systemic lupus erythematosus. IL-2 is decisive for loss of tolerance].Zeitschrift fur Rheumatologie · 2016Review
- The IL-23-IL-17 axis in inflammatory arthritis.Nature reviews. Rheumatology · 2015Review
- Cytokine crowdsourcing: multicellular production of TH17-associated cytokines.Journal of leukocyte biology · 2015Review
- IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013Article
- The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer.Clinical immunology (Orlando, Fla.) · 2013Review
- Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells.The Journal of experimental medicine · 2013Article
- Heat shock protein bystander antigens for peptide immunotherapy in autoimmune disease.Clinical and experimental immunology · 2013Review
- Correlations between psoriasis and inflammatory bowel diseases.BioMed research international · 2013Review
- Rheumatoid Fibroblast-like Synoviocytes Downregulate Foxp3 Expression by Regulatory T Cells Via GITRL/GITR Interaction.Immune network · 2012Article
- Metabolic regulation of organelle homeostasis in lupus T cells.Clinical immunology (Orlando, Fla.) · 2012Review
- Interleukin-17 drives pulmonary eosinophilia following repeated exposure to Aspergillus fumigatus conidia.Infection and immunity · 2012Article
Corrections and comments
- Retraction · 2010-06-01Concerns/Issues about Data · Investigation by Company/Institution · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author · Results Not Reproducible · · Suresh Radhakrishnan has institutional finding of misconduct
- Retracted
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Lymphocyte differentiation from naive CD4(+) T cells into mature Th1, Th2, Th17, or T regulatory cell (Treg) phenotypes has been considered end stage in character. In this study, we demonstrate that dendritic cells (DCs) activated with a novel immune modulator B7-DC XAb (DC(XAb)) can reprogram Tregs into T effector cells. Down-regulation of FoxP3 expression after either in vitro or in vivo Treg-DC(XAb) interaction is Ag-specific, IL-6-dependent, and results in the functional reprogramming of the mature T cell phenotype. The reprogrammed Tregs cease to express IL-10 and TGFbeta, fail to suppress T cell responses, and gain the ability to produce IFN-gamma, IL-17, and TNF-alpha. The ability of IL-6(+) DC(XAb) and the inability of IL-6(-/-) DC(XAb) vaccines to protect animals from lethal melanoma suggest that exogenously modulated DC can reprogram host Tregs. In support of this hypothesis and as a test for Ag specificity, transfer of DC(XAb) into RIP-OVA mice causes a break in immune tolerance, inducing diabetes. Conversely, adoptive transfer of reprogrammed Tregs but not similarly treated CD25(-) T cells into naive RIP-OVA mice is also sufficient to cause autoimmune diabetes. Yet, treatment of normal mice with B7-DC XAb fails to elicit generalized autoimmunity. The finding that mature Tregs can be reprogrammed into competent effector cells provides new insights into the plasticity of T cell lineage, underscores the importance of DC-T cell interaction in balancing immunity with tolerance, points to Tregs as a reservoir of autoimmune effectors, and defines a new approach for breaking tolerance to self Ags as a strategy for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.